▲ The mainland biopharmaceutical company Saisheng Pharmaceutical (new listing code: 06600) will offer shares from Friday (19th) to next Wednesday (24th).
The mainland biopharmaceutical company Saisheng Pharmaceutical (new listing code: 06600) will offer shares from Friday (19th) to next Wednesday (24th), and will be listed on March 3. Based on data from multiple brokerage firms, by 7 pm, Saisheng Pharmaceutical’s margin trading had recorded 46.625 billion yuan, which has been oversubscribed by 212.8 times. Among them, Phillip lent 12 billion yuan, Yaocai lent 8.2 billion yuan, Futu lent 7.36 billion yuan, and UOB Kayxian lent 4.6 billion yuan.
How many hands are drawn for Saisheng Pharmaceutical, can you secure one hand first?See【Next page】
Saisheng Pharmaceutical’s prospectus details:【Next page】
See the prospectus information of Saisheng Pharmaceutical：
Saisheng Pharmaceuticals focuses on treatment areas with significant unmet medical needs, including tumors and severe infections. The company plans to issue 116 million shares and raise up to 2.18 billion yuan. Morgan Stanley, CICC and Credit Suisse are the joint sponsors.
The predecessor of SciClone US, SciClone US, was once listed on NASDAQ (stock code before delisting: SCLN). In 2017, it was privatized by a consortium composed of Telford Capital, Bank of China Group Investment Co., Ltd., CDH Investment, Shangda Capital, and Boying Investment.
I want to easily draw new shares and win money!Download now for free[Click here]
Editor: Lai Yiling